The financials
ACADIA Pharmaceuticals Inc. by the numbers
ACADIA Pharmaceuticals Inc. (ACAD) reported revenue of $268M in Q1 2026 (quarter ended March 31, 2026), up 9.7% from the same quarter a year earlier. That came with a gross margin of 91% and net income of $3.6M (1.4% of revenue). For the full year FY2025, revenue was $1.07B (+12% year on year) and net income $391M. Its largest product in 2026-Q1 was Nuplazid at $167M, 62% of the disclosed total, just ahead of Daybue at 38%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $268M | $244M | +9.7% |
| Gross profit | $243M | $224M | +8.6% |
| Operating income | −$4.6M | $19M | to a loss |
| Net income | $3.6M | $19M | −81% |
| Diluted EPS | $0.02 | $0.11 | −82% |
| Product | Revenue | Share |
|---|---|---|
| Nuplazid | $167M | 62% |
| Daybue | $101M | 38% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $268.1M (-3.8%)
Daybue grew +20% year on yearNuplazid +4.5% year on year
Segment Latestquarter on quarteryear on year
- Nuplazid$166.9M$166.9MQoQ -6.0%year on year +4.5%-6.0%+4.5%
- Daybue$101.1M$101.1MQoQ +0.03%year on year +20%+0.03%+20%